Real‐world glycated haemoglobin changes among type 2 diabetes mellitus patients treated with a maintenance dose of 7 mg or 14 mg of oral semaglutide

Documenti analoghi

• Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
  di: Emily R. Hankosky, et al.
  Pubblicazione: (2025)
• Comment on “Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes”
  di: Manish R. Bhise, et al.
  Pubblicazione: (2025)
• Association between glycated haemoglobin A 1c and total haemoglobin mass in adults with type 1 diabetes mellitus. A proof‐of‐concept study
  di: Janis Schierbauer, et al.
  Pubblicazione: (2025)
• Association of dipeptidyl peptidase‐4 inhibitor initiation at glycated haemoglobin <7.5% with reduced major clinical events mediated by low glycated haemoglobin variability
  di: Johnny T. K. Cheung, et al.
  Pubblicazione: (2024)
• Beyond glycated haemoglobin: Modelling contemporary management of type 2 diabetes with the updated Cardiff model
  di: Phil McEwan, et al.
  Pubblicazione: (2025)